Drug Profile
Research programme: diabetes therapy - Organon
Alternative Names: Org 211559Latest Information Update: 16 Nov 2009
Price :
$50
*
At a glance
- Originator Organon
- Class
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 19 Nov 2007 Organon has been acquired by Schering-Plough
- 25 Jan 2007 Preclinical trials in Diabetes mellitus in USA (unspecified route)